Can a stable adult patient on pregabalin be prescribed a 90‑day supply with up to two refills?

Pregabalin Prescribing: 90-Day Supply with Refills

Yes, pregabalin can be prescribed for a 90-day supply with refills for stable adult patients, as it is not a federally controlled substance in the United States and is not subject to the same prescribing restrictions as opioids or benzodiazepines.

Regulatory Status

Pregabalin is classified as a Schedule V controlled substance at the federal level in the United States 1. However, Schedule V medications have the least restrictive controls among scheduled drugs and can be prescribed with refills. Unlike Schedule II medications (such as most opioids), there are no federal limitations on:

• The duration of the prescription (30,60, or 90 days)
• The number of refills authorized (typically up to 5 refills within 6 months)
• Electronic prescribing requirements

Clinical Considerations for Extended Prescriptions

When prescribing pregabalin for 90 days with refills, ensure the patient meets these criteria:

Patient Stability Requirements:

• Established on a stable, effective dose for their condition
• Demonstrated adherence to the prescribed regimen
• No concerning adverse effects requiring frequent monitoring
• No evidence of misuse or diversion risk

Appropriate Dosing Context: The FDA-approved dosing varies by indication 1:

• Diabetic peripheral neuropathy: Maximum 300 mg/day (100 mg three times daily)
• Postherpetic neuralgia: 150-300 mg/day, up to 600 mg/day for refractory cases
• Fibromyalgia: 300-450 mg/day
• Neuropathic pain (spinal cord injury): 150-600 mg/day

Important Caveats

State-Level Variations: While federally permissible, some states have enacted additional restrictions on pregabalin prescribing. Check your state's prescription drug monitoring program (PDMP) requirements and any state-specific scheduling that may differ from federal classification.

Renal Function Monitoring: Since pregabalin is eliminated primarily by renal excretion, patients with renal impairment require dose adjustments 1. For patients on long-term therapy with 90-day prescriptions, periodic monitoring of renal function (at minimum annually, or more frequently if risk factors present) is prudent to ensure continued appropriate dosing.

Concurrent Medications: Exercise caution when prescribing extended supplies to patients concurrently using:

• Opioids
• Benzodiazepines
• Z-drugs (sedative-hypnotics)

While combination therapy is sometimes clinically necessary 2, the additive CNS depressant effects warrant closer monitoring intervals, potentially making 30-day prescriptions with monthly follow-up more appropriate than 90-day supplies.

Misuse Potential: Recent epidemiological data shows increasing pregabalin use and potential for misuse, particularly in males, patients with lower socioeconomic status, and those aged 35-54 years 3. Higher-risk populations may benefit from shorter prescription durations with more frequent monitoring rather than 90-day supplies.

Practical Prescribing Algorithm

For 90-day prescriptions with refills:

1. Initial titration phase: Use 30-day prescriptions without refills during dose optimization (typically 4-8 weeks) 4, 5

2. Stabilization confirmation: Once stable dose achieved, prescribe one 30-day supply to confirm tolerability

3. Extended prescribing: After demonstrating stability (typically 2-3 months total), transition to 90-day prescriptions with up to 2 refills (covering 9 months total)

4. Monitoring schedule: See patients at least every 6 months for clinical reassessment, even with 90-day prescriptions

5. PDMP review: Check state prescription drug monitoring program at initiation and periodically (frequency varies by state law)

Contraindications to extended prescriptions:

• Active substance use disorder
• Concurrent high-dose opioid therapy (≥50 MME/day) 6, 7
• Unstable psychiatric conditions
• Progressive renal disease requiring frequent dose adjustments
• History of medication diversion
• Patient request for more frequent monitoring